Download CenterVue Launches Fixation Training Module

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Human eye wikipedia, lookup

Eyeglass prescription wikipedia, lookup

Vision therapy wikipedia, lookup

Visual impairment due to intracranial pressure wikipedia, lookup

Mitochondrial optic neuropathies wikipedia, lookup

Retinitis pigmentosa wikipedia, lookup

Visual impairment wikipedia, lookup

Macular degeneration wikipedia, lookup

Diabetic retinopathy wikipedia, lookup

Transcript
FOR IMMEDIATE RELEASE
CenterVue Launches Fixation Training Module to Help Low Vision Patients with
Central Vision Loss
Fremont, Calif. and Padova, Italy – July 27, 2016 – CenterVue Inc. (CenterVue), a leader in
the eye care diagnostics field, announces it has received 510(k) clearance for Fixation Training
for the MAIA platform, an innovative technology designed to help patients rehabilitate from
vision loss using audio feedback. The designation will permit CenterVue to initiate clinical trials
of the device and to continue development of a technology that may help patients improve
vision.
The MAIA Microperimeter is used to assess a patient’s visual function and fixation stability.
Fixation Training can be utilized if the area of fixation within a patient’s retina is inadequate to
provide stable vision. A projected stimulus is moved to a different position and an auditory tone
is used to signal to the patient that stable vision has been achieved. By repeated test and response
using the auditory signals, the patient learns to reposition his or her eye to achieve improved
fixation stability. Improved fixation stability can allow a patient to regain the ability to read,
recognize faces and achieve an overall improved quality of life.
“With the development of Fixation Training for the MAIA, CenterVue is demonstrating its
commitment to the growing number of individuals around the world living with low vision.
Studies have shown that the number of patients with decreased vision due to macular disease,
glaucoma and diabetes will double in the next 15 years. It will be critically important to ensure
that these individuals have the best ability to live fulfilling lives with no trade off in quality of
life due to visual compromise,” said William Burnham, OD, CEO of CenterVue, Inc.
“Fixation stability is a critically important element to successful vision rehabilitation. This
modality would add to the already powerful clinical utility of the MAIA Microperimeter. I look
forward to the outcomes of research with the Fixation Training module and the potential it offers
to my patients,” said Dr. Samuel N. Markowitz, MDFRCS(C), Director, Low Vision
Rehabilitation Program, Department of Ophthalmology, University of Toronto.
CenterVue designs and manufactures advanced technology in eye care diagnostics. CenterVue
products are sold in over 70 countries worldwide.
For more information on any of CenterVue’s products please visit www.centervue.com or email
infous@centervue.com
1
About CenterVue
CenterVue is a privately held company headquarter in Padova, Italy, with a US subsidiary
located in Fremont, CA. CenterVue develops diagnostic systems for the early detection of sightthreatening pathologies, such as Diabetic Retinopathy and Macular Degeneration. The
company’s goal is to reduce preventable blindness in diabetic and aging patients. CenterVue
integrates the most advanced technologies to develop superior diagnostic instruments for eye
care. With over 3000 installations worldwide, CenterVue’s in-house research and product
development have helped doctors worldwide with the implementation of global screening
programs for early detection of ocular pathologies and vision disorders.
Company contact:
Jill Rogers
Director of Marketing
CenterVue, Inc.
jill.rogers@centervue.com
408.988.8404
###
2